ORAMED PHARMACEUTICALS INC. Earnings Per Share Disclosure
NOTE 16 – INCOME (LOSS) PER SHARE OF COMMON STOCK:
The following table summarizes the calculation of basic and diluted income per common stock (in thousands, except for share and per share amounts):
| Year ended December 31, | ||||||||
| 2025 | 2024 | |||||||
| Basic income (loss) per common stock (numerator): | ||||||||
| Net income (loss) applicable to common stock | 64,050 | (19,060 | ) | |||||
| Adjustment for dividends attributable to unvested RSUs | (808 | ) | ||||||
| Net income (loss) applicable to common stock – basic | 63,242 | (19,060 | ) | |||||
| common stock (denominator): | ||||||||
| Weighted average number of common stock – basic | 41,402,997 | 40,850,446 | ||||||
| Basic income (loss) per common stock | 1.53 | (0.48 | ) | |||||
| Diluted income (loss) per common stock (numerator): | ||||||||
| Net income (loss) applicable to common stock – basic | 63,242 | (19,060 | ) | |||||
| Adjustment for dividends attributable to unvested RSUs | 359 | |||||||
| Net income (loss) applicable to common stock – diluted | 63,601 | (19,060 | ) | |||||
| common stock (denominator): | ||||||||
| Weighted average number of common stock – basic | 41,402,997 | 40,850,446 | ||||||
| Diluted effect of RSUs | 1,015,647 | |||||||
| Weighted average number of common stock – diluted | 42,418,644 | 40,850,446 | ||||||
| Diluted income (loss) per common stock | 1.50 | (0.48 | ) | |||||
For the year ended December 31, 2025, options to purchase common stock, RSUs and warrants totaling 1,847,946 were excluded from the calculation of diluted income per common stock, as their effect was antidilutive. As the Company had a net loss for the year ended December 31, 2024, all potentially dilutive common stock, including options, warrants and RSUs totaling 3,549,490, were considered antidilutive and therefore excluded from the calculation of diluted income per common stock for the period.
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.